Medical Weight Loss & GLP-1 Programs
Tirzepatide — Dual GIP/GLP-1 Weight Loss
Tirzepatide is the first dual-receptor agonist approved for weight management — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual mechanism has translated, in head-to-head trials, into greater average weight loss than GLP-1 monotherapy. At Vivere Drip Therapy in Carmel and Salinas, CA, tirzepatide is offered to qualified candidates as a once-weekly injection within a structured program.
How Tirzepatide Works
GLP-1 activation alone slows gastric emptying, reduces appetite, and improves insulin response. Adding GIP activation appears to enhance the metabolic response further — improving glucose handling and producing greater fat-mass reductions in clinical study. The combined receptor activity is thought to explain why tirzepatide consistently outperforms semaglutide in average weight-loss results, though individual response varies significantly.
Dosing & Titration
Tirzepatide is a once-weekly subcutaneous injection. Initial dosing starts low (2.5 mg) and is titrated upward every four weeks as tolerated, with maintenance doses typically ranging from 5 mg to 15 mg. As with semaglutide, slow titration is the most reliable way to manage gastrointestinal side effects. Your provider will personalize the pace and target dose based on tolerance, weight-loss response, and goals.
Expected Results
Phase 3 trials of tirzepatide showed average weight loss of approximately 20–22% of body weight at the highest dose over 72 weeks — meaningfully greater than what has been observed with GLP-1 monotherapy in similar populations. As always, individual results vary, and sustained outcomes require pairing the medication with consistent nutrition, protein-forward eating to protect lean mass, and regular activity.
Frequently Asked Questions
Is Tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active ingredient in both Mounjaro (approved for diabetes) and Zepbound (approved for weight loss). Compounded tirzepatide is the same molecule formulated through a licensed compounding pharmacy. Your provider will discuss which formulation is appropriate for your program.
Is Tirzepatide better than Semaglutide?
On average, tirzepatide produces greater weight loss in clinical trials. That said, individual response varies, and some patients tolerate semaglutide better. Choice of medication depends on your health history, prior response, tolerance, cost considerations, and clinician judgment.
Who is not a good candidate for Tirzepatide?
Tirzepatide is not appropriate for patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or pregnancy. Your provider will review your full health history before prescribing.
These therapies are offered as part of individualized medical weight-loss programs supervised by a licensed clinician and are not a substitute for evaluation of underlying medical conditions. Suitability, dosing, and program structure are determined by your provider based on your full health history. Information provided here is educational, not medical advice.
Related Topics
Book a Consultation
Every weight-loss program at Vivere is individualized. Book a consultation at our Carmel or Salinas clinic — or via telehealth from anywhere in the U.S. — to learn whether GLP-1 therapy is the right next step for you.